person · Reporting owner

GRAY SUSANNAH

Disclosed activity across 6 companies

Tapewire entity: 36682
SEC CIK: 0001833453

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
4D Molecular Therapeutics, Inc.FDMT · Entity 2419	Director	June 17, 2026	June 18, 2026
ANAPTYSBIO, INCANAB · Entity 4640	Director	April 27, 2026	April 29, 2026
MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291	Director	May 26, 2026	May 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

4D Molecular Therapeutics, Inc.

Report date June 17, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16	Direct	50,000	Reported balance After 2026-06-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-17 · Grant · Acquired 50,000 · Balance 50,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Filing footnotes · ownership attribution and instrument terms

F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

ANAPTYSBIO, INC

Report date April 27, 2026 · Filed April 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	11,250	Reported balance After 2026-04-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-27 · Grant · Acquired 11,250 · Balance 11,250 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2: 1/3 of the RSUs shall vest on April 27, 2027 and 1/3 of the RSUs shall vest in equal annual installments until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F2: 1/3 of the RSUs shall vest on April 27, 2027 and 1/3 of the RSUs shall vest in equal annual installments until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

MARAVAI LIFESCIENCES HOLDINGS, INC.

Report date May 26, 2026 · Filed May 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	216,200	Reported balance After 2026-05-26 transaction · row 1 1 source row Row 1 · 2026-05-26 · Grant · Acquired 46,293 · Balance 216,200 F1: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Apria, Inc.

Report date March 29, 2022 · Filed March 29, 2022

Section 16 reporting ended · disclosed 2022-03-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-03-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-03-29 · Disposition to issuer · Disposed 5,059 · Balance 0 F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee. F1: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F4: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F2: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee.

F3: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration.

F4: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date.

Morphic Holding, Inc.

Report date August 16, 2024 · Filed August 20, 2024

Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.46 · Expires 2031-04-26	Direct	Reported balance After 2024-08-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-08-16 · Disposition to issuer · Disposed 18,111 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") vested as to 25% of the total shares on April 27, 2022, and 9.375% of the remaining shares vests quarterly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2032-06-08	Direct	Reported balance After 2024-08-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-08-16 · Disposition to issuer · Disposed 17,550 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5: The Option is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.47 · Expires 2033-05-31	Direct	Reported balance After 2024-08-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-08-16 · Disposition to issuer · Disposed 12,535 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5: The Option is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.52 · Expires 2034-06-03	Direct	Reported balance After 2024-08-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-08-16 · Disposition to issuer · Disposed 23,168 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.

F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.

F3: The Company Stock Option ("Option") vested as to 25% of the total shares on April 27, 2022, and 9.375% of the remaining shares vests quarterly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date.

F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.

F5: The Option is fully vested.

F6: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.

Theravance Biopharma, Inc.

Report date September 23, 2026 · Filed September 25, 2026

Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Ending reported balance After 2026-09-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-23 · Disposition to issuer · Disposed 42,137 · Balance 6,009 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 6,009 · Balance 0 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.87 · Expires 2033-02-25	Direct	Reported balance After 2026-09-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-23 · Disposition to issuer · Disposed 32,666 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.95 · Expires 2033-05-01	Direct	Reported balance After 2026-09-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-23 · Disposition to issuer · Disposed 22,044 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.49 · Expires 2034-05-07	Direct	Reported balance After 2026-09-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-23 · Disposition to issuer · Disposed 23,576 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.39 · Expires 2035-05-18	Direct	Reported balance After 2026-09-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-09-23 · Disposition to issuer · Disposed 24,258 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.64 · Expires 2036-06-11	Direct	Reported balance After 2026-09-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-09-23 · Disposition to issuer · Disposed 13,398 · Balance 0 F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.

F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 23, 2026 Filed Sep 25, 2026 00:31 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	Disposition to issuerShare Option (Right to Buy) · Derivative	13,398	Not disclosed Strike: $16.64	Not disclosed	Disclosure SEC source: 0001833453-26-000009 · form4-09252026_120921.xml · derivative · entry 7 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,398 shares Expires 2036-06-11 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. Read SEC document
September 23, 2026 Filed Sep 25, 2026 00:31 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	Disposition to issuerShare Option (Right to Buy) · Derivative	24,258	Not disclosed Strike: $9.39	Not disclosed	Disclosure SEC source: 0001833453-26-000009 · form4-09252026_120921.xml · derivative · entry 6 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 24,258 shares Expires 2035-05-18 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. Read SEC document
September 23, 2026 Filed Sep 25, 2026 00:31 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	Disposition to issuerShare Option (Right to Buy) · Derivative	23,576	Not disclosed Strike: $9.49	Not disclosed	Disclosure SEC source: 0001833453-26-000009 · form4-09252026_120921.xml · derivative · entry 5 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 23,576 shares Expires 2034-05-07 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. Read SEC document
September 23, 2026 Filed Sep 25, 2026 00:31 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	Disposition to issuerShare Option (Right to Buy) · Derivative	22,044	Not disclosed Strike: $10.95	Not disclosed	Disclosure SEC source: 0001833453-26-000009 · form4-09252026_120921.xml · derivative · entry 4 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,044 shares Expires 2033-05-01 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. Read SEC document
September 23, 2026 Filed Sep 25, 2026 00:31 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	Disposition to issuerShare Option (Right to Buy) · Derivative	32,666	Not disclosed Strike: $9.87	Not disclosed	Disclosure SEC source: 0001833453-26-000009 · form4-09252026_120921.xml · derivative · entry 3 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 32,666 shares Expires 2033-02-25 F3 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. F3 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. Read SEC document
September 23, 2026 Filed Sep 25, 2026 00:31 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	Disposition to issuerOrdinary Shares	6,009	Not disclosed	Not disclosed	Disclosure SEC source: 0001833453-26-000009 · form4-09252026_120921.xml · nonDerivative · entry 2 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. Read SEC document
September 23, 2026 Filed Sep 25, 2026 00:31 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	Disposition to issuerOrdinary Shares	42,137	Not disclosed	Not disclosed	Disclosure SEC source: 0001833453-26-000009 · form4-09252026_120921.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,009 F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Read SEC document
June 17, 2026 Filed Jun 18, 2026 21:39 UTC	4D Molecular Therapeutics, Inc. FDMT · Entity 2419	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $9.42	$0.00	Disclosure SEC source: 0001193125-26-276160 · ownership.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-06-16 F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document
June 12, 2026 Filed Jun 17, 2026 01:39 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	13,398	$0.00 Strike: $16.64	$0.00	Disclosure SEC source: 0001833453-26-000006 · form4-06172026_010638.xml · derivative · entry 2 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,398 Underlying: Ordinary Shares · 13,398 shares Expires 2036-06-11 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document
June 12, 2026 Filed Jun 17, 2026 01:39 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	6,009	$0.00	$0.00	Disclosure SEC source: 0001833453-26-000006 · form4-06172026_010638.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,146 Read SEC document
May 26, 2026 Filed May 28, 2026 22:27 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	GrantClass A Common Stock	46,293	$0.00	$0.00	Disclosure SEC source: 0001833453-26-000004 · wk-form4_1780007234.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,200 F1 · shares: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. Read SEC document
April 27, 2026 Filed Apr 29, 2026 20:05 UTC	ANAPTYSBIO, INC ANAB · Entity 4640	GrantRestricted Stock Unit · Derivative	11,250	$0.00	$0.00	Disclosure SEC source: 0001833453-26-000003 · form4-04292026_040401.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 1/3 of the RSUs shall vest on April 27, 2027 and 1/3 of the RSUs shall vest in equal annual installments until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: 1/3 of the RSUs shall vest on April 27, 2027 and 1/3 of the RSUs shall vest in equal annual installments until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
June 17, 2025 Filed Jun 20, 2025 20:05 UTC	4D Molecular Therapeutics, Inc. FDMT · Entity 2419	GrantStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $4.15	$0.00	Disclosure SEC source: 0000950170-25-088496 · ownership.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2035-06-16 F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document
June 16, 2025 Filed Jun 18, 2025 22:25 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	GrantClass A Common Stock	89,139	$2.16	$192,540.24	Disclosure SEC source: 0001823239-25-000088 · wk-form4_1750285512.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,907 F1 · shares: Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders Read SEC document
May 19, 2025 Filed May 21, 2025 23:13 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	24,258	$0.00 Strike: $9.39	$0.00	Disclosure SEC source: 0001415889-25-014009 · form4-05212025_110557.xml · derivative · entry 2 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,258 Underlying: Ordinary Shares · 24,258 shares Expires 2035-05-18 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document
May 19, 2025 Filed May 21, 2025 23:13 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	10,649	$0.00	$0.00	Disclosure SEC source: 0001415889-25-014009 · form4-05212025_110557.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,137 Read SEC document
August 16, 2024 Filed Aug 20, 2024 19:07 UTC	Morphic Holding, Inc. MORF · Entity 88114	Disposition to issuerStock Option (Right to Buy) · Derivative	23,168	Not disclosed Strike: $30.52	Not disclosed	Disclosure SEC source: 0001415889-24-021759 · form4-08202024_110840.xml · derivative · entry 4 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,168 shares Expires 2034-06-03 F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
August 16, 2024 Filed Aug 20, 2024 19:07 UTC	Morphic Holding, Inc. MORF · Entity 88114	Disposition to issuerStock Option (Right to Buy) · Derivative	12,535	Not disclosed Strike: $56.47	Not disclosed	Disclosure SEC source: 0001415889-24-021759 · form4-08202024_110840.xml · derivative · entry 3 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,535 shares Expires 2033-05-31 F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The Option is fully vested. Read SEC document
August 16, 2024 Filed Aug 20, 2024 19:07 UTC	Morphic Holding, Inc. MORF · Entity 88114	Disposition to issuerStock Option (Right to Buy) · Derivative	17,550	Not disclosed Strike: $24.49	Not disclosed	Disclosure SEC source: 0001415889-24-021759 · form4-08202024_110840.xml · derivative · entry 2 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,550 shares Expires 2032-06-08 F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The Option is fully vested. Read SEC document
August 16, 2024 Filed Aug 20, 2024 19:07 UTC	Morphic Holding, Inc. MORF · Entity 88114	Disposition to issuerStock Option (Right to Buy) · Derivative	18,111	Not disclosed Strike: $55.46	Not disclosed	Disclosure SEC source: 0001415889-24-021759 · form4-08202024_110840.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,111 shares Expires 2031-04-26 F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company Stock Option ("Option") vested as to 25% of the total shares on April 27, 2022, and 9.375% of the remaining shares vests quarterly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
June 04, 2024 Filed Jun 5, 2024 19:11 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantCommon Stock · Derivative	23,168	$0.00 Strike: $30.52	$0.00	Disclosure SEC source: 0001415889-24-015666 · form4-06052024_110614.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,168 Underlying: Common Stock · 23,168 shares Expires 2034-06-03 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
May 23, 2024 Filed May 24, 2024 21:57 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	GrantClass A Common Stock	20,645	$10.78	$222,553.10	Disclosure SEC source: 0001823239-24-000072 · wk-form4_1716587818.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,768 F1 · shares: Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. Read SEC document
May 21, 2024 Filed May 23, 2024 23:10 UTC	4D Molecular Therapeutics, Inc. FDMT · Entity 2419	GrantStock Option (Right To Buy) · Derivative	22,500	$0.00 Strike: $25.15	$0.00	Disclosure SEC source: 0000950170-24-064208 · ownership.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2034-05-20 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 21, 2025 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 21, 2027. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document
May 08, 2024 Filed May 10, 2024 22:06 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	23,576	$0.00 Strike: $9.49	$0.00	Disclosure SEC source: 0001415889-24-012913 · form4-05102024_100550.xml · derivative · entry 2 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,576 Underlying: Ordinary Shares · 23,576 shares Expires 2034-05-07 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document
May 08, 2024 Filed May 10, 2024 22:06 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	10,537	$0.00	$0.00	Disclosure SEC source: 0001415889-24-012913 · form4-05102024_100550.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,488 Read SEC document
July 17, 2023 Filed Jul 19, 2023 20:49 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	GrantClass A Common Stock	24,000	$0.00	$0.00	Disclosure SEC source: 0001823239-23-000059 · wf-form4_168979974373678.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,123 F1 · shares: Represents restricted stock units granted on July 17, 2023, which vest in full upon the earlier of one year from the date of grant or the date of the 2024 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders. Read SEC document
June 01, 2023 Filed Jun 2, 2023 19:05 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantDirector Stock Option (Right to Buy) · Derivative	12,535	$0.00 Strike: $56.47	$0.00	Disclosure SEC source: 0001209191-23-034041 · doc4.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,535 Underlying: Common Stock · 12,535 shares Expires 2033-05-31 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 1, 2024 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
May 23, 2023 Filed May 25, 2023 23:33 UTC	4D Molecular Therapeutics, Inc. FMDT · Entity 2419	GrantStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $17.98	$0.00	Disclosure SEC source: 0001610717-23-000069 · form4.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2033-05-22 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2024 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2026. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document
May 02, 2023 Filed May 4, 2023 22:38 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	22,044	$0.00 Strike: $10.95	$0.00	Disclosure SEC source: 0001415889-23-007376 · form4-05042023_100555.xml · derivative · entry 2 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,044 Underlying: Ordinary Shares · 22,044 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date. Read SEC document
May 02, 2023 Filed May 4, 2023 22:38 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	9,132	$0.00	$0.00	Disclosure SEC source: 0001415889-23-007376 · form4-05042023_100555.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,951 Read SEC document
February 26, 2023 Filed Mar 1, 2023 01:17 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	4,666	$0.00 Strike: $9.87	$0.00	Disclosure SEC source: 0001415889-23-003569 · form4-03012023_010311.xml · derivative · entry 4 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,666 Underlying: Ordinary Shares · 4,666 shares Expires 2033-02-25 F2 · derivative.exercise_date: This option shall vest monthly over two months of service from the date of grant and will vest in full upon earlier of the two-month anniversary of Susannah Gray's appointment to the Board or the date of Company's 2023 annual meeting of Shareholders. Read SEC document
February 26, 2023 Filed Mar 1, 2023 01:17 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantShare Option (Right to Buy) · Derivative	28,000	$0.00 Strike: $9.87	$0.00	Disclosure SEC source: 0001415889-23-003569 · form4-03012023_010311.xml · derivative · entry 3 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Ordinary Shares · 28,000 shares Expires 2033-02-25 F1 · derivative.exercise_date: The option vests monthly over 24 months of service from the date of grant. Read SEC document
February 26, 2023 Filed Mar 1, 2023 01:17 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	1,688	$0.00	$0.00	Disclosure SEC source: 0001415889-23-003569 · form4-03012023_010311.xml · nonDerivative · entry 2 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,819 Read SEC document
February 26, 2023 Filed Mar 1, 2023 01:17 UTC	Theravance Biopharma, Inc. TBPH · Entity 5037	GrantOrdinary Shares	10,131	$0.00	$0.00	Disclosure SEC source: 0001415889-23-003569 · form4-03012023_010311.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,131 Read SEC document
June 08, 2022 Filed Jun 10, 2022 19:00 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantDirector Stock Option (Right to Buy) · Derivative	17,550	$0.00 Strike: $24.49	$0.00	Disclosure SEC source: 0001209191-22-036118 · doc4.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,550 Underlying: Common Stock · 17,550 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 8, 2023 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
May 23, 2022 Filed May 25, 2022 23:01 UTC	4D Molecular Therapeutics, Inc. FDMT · Entity 2419	GrantStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $7.77	$0.00	Disclosure SEC source: 0001567619-22-011719 · doc1.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2032-05-22 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document
March 29, 2022 Filed Mar 29, 2022 16:30 UTC	Apria, Inc. APR · Entity 15495	Disposition to issuerRestricted Stock Units · Derivative	5,059	$37.50	$189,712.50	Disclosure SEC source: 0000899243-22-012658 · doc4.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,059 shares Expires not disclosed F2 · derivative.exercise_price: Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee. F1 · kind: On March 29, 2022, Owens & Minor, Inc. ("Owens & Minor") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the "Merger Agreement"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax. F3 · kind: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F3 · price: Pursuant to the Merger Agreement, each restricted stock unit ("RSU") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration. F4 · derivative.exercise_date: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date. F4 · derivative.expiration_date: Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date. Read SEC document
November 19, 2021 Filed Nov 23, 2021 21:16 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	GrantClass A Common Stock	4,271	$0.00	$0.00	Disclosure SEC source: 0000899243-21-045773 · doc4.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,123 F1 · shares: Represents restricted stock units ("RSUs") granted on November 19, 2021, which vest in full one year from the date of the grant. Read SEC document
June 16, 2021 Filed Jun 17, 2021 19:10 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantDirector Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $64.79	$0.00	Disclosure SEC source: 0001209191-21-041687 · doc4.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 16, 2022 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. Read SEC document
June 16, 2021 Filed Apr 29, 2022 16:12 UTC Amendment	Morphic Holding, Inc. MORF · Entity 88114	GrantDirector Stock Option (right to buy) · Derivative	0	$0.00 Strike: $64.79	$0.00	Disclosure SEC source: 0001209191-22-026234 · doc4a.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2031-06-16 F1 · shares: This Form 4 is being amended to reflect the amount actually granted, as the originally reported share number was in error. F2 · derivative.exercise_date: Not applicable. Read SEC document
June 10, 2021 Filed Jun 14, 2021 19:40 UTC	Apria, Inc. APR · Entity 15495	GrantRestricted Stock Units · Derivative	5,059	$0.00	$0.00	Disclosure SEC source: 0000899243-21-023693 · doc4.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,059 Underlying: Common Stock · 5,059 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer ("Common Stock"). The restricted stock units will be settled in either Common Stock or cash (or a combination thereof) at the discretion of the Issuer's compensation committee. F2 · derivative.exercise_date: These restricted stock units vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date. F2 · derivative.expiration_date: These restricted stock units vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date. Read SEC document
May 17, 2021 Filed May 20, 2021 00:30 UTC	4D Molecular Therapeutics, Inc. FDMT · Entity 2419	GrantStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $26.89	$0.00	Disclosure SEC source: 0001567619-21-010745 · doc1.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-05-16 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document
April 27, 2021 Filed Apr 29, 2021 19:10 UTC	Morphic Holding, Inc. MORF · Entity 88114	GrantStock Option (right to buy Common Stock) · Derivative	24,000	$0.00 Strike: $55.46	$0.00	Disclosure SEC source: 0001209191-21-029109 · doc4.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2031-04-26 F1 · derivative.exercise_date: The option vests as to 25% of the total shares on April 27, 2022, and then 9.375% of the remaining shares shall vest quarterly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
April 27, 2021 Filed Apr 29, 2022 16:14 UTC Amendment	Morphic Holding, Inc. MORF · Entity 88114	GrantStock Option (right to buy Common Stock) · Derivative	18,111	$0.00 Strike: $55.46	$0.00	Disclosure SEC source: 0001209191-22-026235 · doc4a.xml · derivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,111 Underlying: Common Stock · 18,111 shares Expires 2031-04-26 F1 · shares: This Form 4 is being amended to reflect the amount actually granted, as the originally reported share number was in error. F2 · derivative.exercise_date: The option vests as to 25% of the total shares on April 27, 2022, and then 9.375% of the remaining shares shall vest quarterly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
November 24, 2020 Filed Nov 26, 2020 00:58 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	PurchaseClass A Common Stock	20,000	$27.00	$540,000.00	Disclosure SEC source: 0000899243-20-032223 · doc4.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,852 Read SEC document
November 19, 2020 Filed Nov 23, 2020 22:27 UTC	MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291	GrantClass A Common Stock	11,852	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031935 · doc4.xml · nonDerivative · entry 1 GRAY SUSANNAH · CIK 0001833453 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,852 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.